في ذكرى يومنا الوطني، نحمد الله على ما تحقق من إنجازات في بلادنا الغالية، ووحدة وطنية قامت على الشريعة الإسلامية والعدل.

✨ نبارك للجامعات المتأهلة للمرحلة الثانية من مسابقة التثقيف الدوائي في #IHOP7 الحماس يزيد… والتحدي يكبر! 🚀 #قادة_في_التغيير

The 3rd Student Competition at the 5th Annual Saudi Pharmacoeconomics and Outcomes Research Conference showcases the brightest young minds shaping the future of health economics! We are proud to announce the 21st university competing: جامعة الملك فيصل Good luck! Register now to

For #criticallyill patients who had both severe metabolic acidemia and moderate to severe acute kidney injury, sodium bicarbonate therapy did not significantly decrease day 90 all-cause mortality. #LIVES2025 ESICM ja.ma/4nsi8jE

Presented at #LIVES2025: In a pragmatic trial conducted in general medical wards with limited diagnostic and therapeutic resources in Kenya, glucocorticoids reduced mortality in patients with community-acquired pneumonia. Full trial results: nej.md/47glh02 Editorial:

This mind-bending @nejm trial randomized septic shock patents to A-line vs cuff BP monitoring The signal showed that outcomes were actually worse in those randomized to A-line. By a bit. So at least cuff monitoring is non-inferior. I find that I am using A-lines less and

😂😂😂

💬 Editorial: Recent trials show intravenous thrombolysis provides no clear benefit for patients presenting to the emergency department with mild stroke (NIHSS 0–5), highlighting the need for highly individualized treatment decisions. ja.ma/4a8qpXc

This independent practice advisory supports early anticoagulation (starting to restarting DOACs) within 48 hours of onset in patients with A Fib and minor (NIHSS ≤5) completed embolic stroke. At least does no harm, and possibly a small (1-2%) reduction in the risk of 30-day

The data has always been out there, hidden in the ATACH-2 and INTERACT-2 trials, but this 2-center observational study really brings the potential dangers of very quick BP reduction in acute #ICH to light... ...both when target (SBP <150 mm Hg) is reached within 2 hours, and

SOFA-2, validated in >3 million ICU patients, incorporates contemporary organ support and treatments, showing strong predictive validity for ICU mortality in diverse international settings. ja.ma/457YYJx

A secondary analysis of the TEMPO-2 RCT found no significant improvement in outcomes for minor ischemic stroke patients treated with intravenous tenecteplase, regardless of the presence of disabling deficits. ja.ma/4aQpc75

💬 Viewpoint: Mass abstract submissions in #MedEd have led to inflated metrics, less meaningful research, and misaligned incentives for trainees and institutions. ja.ma/4qlJES1

Personalized treatment approaches in neurocritical care CCR Journal Watch  criticalcarereviews.com/latest-evidenc…

شكراً على ثقتكم وتهنئتكم سعادة العميد، وأرجوا من الله أن يكون عوناً لنا لخدمة الدين و البلاد و العباد 🌹

#مجتمع_كفو #جامعة_الملك_فيصل

Every year in the United States, >600000 individuals have a first ischemic stroke and approximately 200000 more have a recurrent stroke. This guideline aims to incorporate this updated evidence in order to provide an up-to-date, comprehensive set of recommendations for the acute

The antibiotic minocylcine improved functional outcome (mRS) for people with ischemic stroke in a large randomized trial. Outcomes at 90 days later (Figure). The drug is also a potent anti-inflammatory. thelancet.com/journals/lance…

In patients with non–large-vessel occlusion stroke and salvageable tissue, tenecteplase extended to 24 hours improved outcomes compared with standard care but increased bleeding risk. #ISC26 AHA Science bit.ly/4tj2lrJ